Analyst Ratings for Pacific Biosciences of California (PACB)
PACB Rating Summary
PACB Price Target Summary
- Highest: $3.00 (Canaccord)
- Lowest: $1.35 (UBS)
- Average: $1.97
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$1.97 (+52.7%)
* Over Last 12-Mos
Rating Score: 4.3 / 10
Percentile Rank: 43%
Avg. $ Target:
$1.97 (+52.7%)
* Over Last 12-Mos
Rating Score: 4.3 / 10
Percentile Rank: 43%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/9/2026 | UBS | Douglas Schenkel | New Coverage | Neutral (N/A) |
1.35 (N/A) |
1.32 (1.29) |
-2.27% | Details |
| 3/6/2026 | Barclays » Updated 5/11/2026 |
Luke Sergott | Downgrade | Underweight (Equalweight) |
1.50 (1.00) |
1.52 (1.29) |
-15.13% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
